High-dose Wegovy debuts at $399 for self-paying patients

Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…

AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.

• On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
• On site: Novo rolls out Wegovy HD, sparking access debates (7)
• Regulators press for more GLP-1 safety data and oversight (4)
• Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
• All Other Stories

On scene: industry shifts, IPOs, stigma and miscellaneous reports

On site: Novo rolls out Wegovy HD, sparking access debates

Regulators press for more GLP-1 safety data and oversight

Reporting from clinics: GLP-1s vary in effect, risk muscle loss

All Other Stories